divarasib + cetuximab + FOLFOX

**divarasib + cetuximab + FOLFOX** is an investigational combination therapy consisting of divarasib, cetuximab, and the FOLFOX chemotherapy regimen. Divarasib is an oral small molecule inhibitor targeting KRAS G12C mutant proteins, leading to inhibition of the RAS-mediated signaling pathways involved in cancer cell proliferation and survival. Cetuximab is a monoclonal antibody against the epidermal growth factor receptor (EGFR), blocking downstream signaling in cancer cells and inhibiting tumor growth. FOLFOX is a standard chemotherapy combination that includes folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin, all of which disrupt DNA synthesis and cancer cell division. This combination is primarily investigated in patients with KRAS G12C-mutant metastatic colorectal cancer, particularly in clinical trial settings[1][2][3][6][7].